Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

MasterCraft's fiscal Q1 results exceeded expectations, with dealer visibility starting to improve. Read why I remain at a Buy ...

Bank of America's fourth quarter rounded off a very healthy year for the bank in terms of growth. Learn why BAC stock is a ...

Under Armour is now going through a major brand turnaround as founder Kevin Plank took over as CEO in 2024. Read why I rate ...

Mettler-Toledo International is an interesting company, but not one that comes attractively priced. Read what prompts MTD ...

Nintendo appears ready to capitalize on the excitement with a new Mario Kart game ready for launch. Learn why NTDOY stock is ...

Overall, the production plan of the four companies indicates a positive perspective for Topaz. They expect their production ...

Austal's stock surge was driven by significant contracts and positive guidance for FY25. Click here to read why I maintain a ...

Oxford Lane Capital's valuations are at a lower than usual premium to NAV, making buys more acceptable for CLO investors.

NN, Inc.'s new CEO Harold Bevis, with significant turnaround experience, has initiated cost cuts. Click here to read why NNBR stock is a Strong Buy.

Mastercard is expected to report solid Q4 revenue growth of 13-14%, driven by strong cross-border volumes. Read why I assign ...

Chinese LiDAR companies like Hesai and RoboSense are outpacing Western counterparts. Learn more about the future of LiDAR ...